Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Ivosidenib for the treatment of isocitrate dehydrogenase-1 mutant cholangiocarcinoma.

Expert review of gastroenterology & hepatology - 1 May 2021

Corrigan Lynda, Lowery Maeve

Abstract excerpt

Introduction: Cholangiocarcinomas (CCAs) are associated with poor survival outcomes, with limited treatment options in the unresectable or metastatic setting. A precision medicine approach to cancer treatment has revealed new therapeutic options that provide an alternative to traditional chemotherapeutic strategies. Isocitrate dehydrogenase 1 (IDH1) mutations are identified in approximately 10-15% of CCAs and may...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Bile Duct Neoplasms
Share to Cholangiocarcinoma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glycine

Share to Isocitrate Dehydrogenase

Share to Mutation

Share to Pyridines

Source

Identifiers

PMID: 33836133
DOI: 10.1080/17474124.2021.1915765

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Ivosidenib for the treatment of isocitrate dehydrogenase-1 mutant cholangiocarcinoma.PMID 33836133Read ↗

Ivosidenib in IDH1-mutated cholangiocarcinoma: Clinical evaluation and future directions.Semantic proximity Read ↗

Clinical Utility of Ivosidenib in the Treatment of IDH1-Mutant Cholangiocarcinoma: Evidence To DateSemantic proximity Read ↗

Ivosidenib: A Review in Advanced Cholangiocarcinoma.Semantic proximity Read ↗

Real-World Data on Ivosidenib in Patients with Previously Treated Isocitrate Dehydrogenase 1-Mutated Intrahepatic Cholangiocarcinomas: An Early Exploratory Analysis.Semantic proximity Read ↗

Ivosidenib for IDH1-Mutant Intrahepatic Cholangiocarcinoma: Insights From a Multicenter Real-World Study.Semantic proximity Read ↗

IDH Mutant Cholangiocarcinoma: Pathogenesis, Management, and Future TherapiesSemantic proximity Read ↗

Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.Semantic proximity Read ↗

IDH inhibitors in advanced cholangiocarcinoma: Another arrow in the quiver?Semantic proximity Read ↗

Molecular and morphological changes induced by ivosidenib correlate with efficacy in mutant-IDH1 cholangiocarcinoma.Semantic proximity Read ↗

FDA Approval Summary: Ivosidenib for the Treatment of Patients with Advanced Unresectable or Metastatic, Chemotherapy Refractory Cholangiocarcinoma with an IDH1 Mutation.Semantic proximity Read ↗

Pharmacokinetics/pharmacodynamics of ivosidenib in advanced IDH1-mutant cholangiocarcinoma: findings from the phase III ClarIDHy study.Semantic proximity Read ↗

Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.